Repligen Corporation Common Stock vs Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B), while Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) trades at $6.29 (market cap $22.64B). The key difference: Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) is far larger — about 2× Repligen Corporation Common Stock's market cap, and Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) pays a 0.52% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) for 1 Days on average.
| RGEN | SBS | |
|---|---|---|
Market Cap | $11.31B | $22.64B |
Volume | 1,216,919 | 8,795,741 |
Sector | Health | Utilities |
52-Week High | $194.57 | $7.08 |
52-Week Low | $102.87 | $4.46 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $11.20B | $29.44B |
Dividend Yield | — | 0.52% |
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SBS trades at $6.45, down 4.16% today, with a P/E of 13.54 and a net income margin of 19.71%. Recent earnings showed a Q2 2026 miss after two prior beats. Technical indicators are mixed, with a bullish moving average signal but bearish oscillators. The company reported 2025 revenue of $38.09B and net income of $8.46B, though 2026 projections indicate a slight decline in profit margin to 19.71%.
The outlook is cautious; while valuation metrics appear reasonable and profitability is strong, recent earnings volatility and a negative net cash flow projection for 2026 pose risks. Analyst sentiment is mixed with a 'Hold' consensus, suggesting limited near-term upside potential amid operational headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →Sabesp provides water supply and sewage services in the Brazilian state of São Paulo. Its shares trade in Brazil as SBSP3 and in the U.S. as NYSE-listed ADSs under SBS.
Read more on SBS →